We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MGZ Munich Completes Validation of Higher Resolution v2 CytoChip
News

MGZ Munich Completes Validation of Higher Resolution v2 CytoChip

MGZ Munich Completes Validation of Higher Resolution v2 CytoChip
News

MGZ Munich Completes Validation of Higher Resolution v2 CytoChip

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MGZ Munich Completes Validation of Higher Resolution v2 CytoChip"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Medizinisch Genetisches Zentrum, (MGZ), in Munich, has announced that it has completed the validation of BlueGnome’s recently released version 2.0 CytoChip.

The CytoChip is used in over 14 countries to investigate patients presenting with constitutional genetic disorders. At just over half megabase resolution the v2 CytoChip offers a 50% increase over v1.1, with the majority of extra resolution focused on clinically important sub-telomeric regions.

The v2 CytoChip is supported by a new release of BlueGnome’s arrayCGH analysis software, BlueFuse for Microarrays, which has been optimized for use with the CytoChip.

Dr Nick Haan CEO of BlueGnome, explained, “As an open platform BlueFuse is required to make general assumptions about the microarray being analysed. However with the v2 CytoChip we took the opportunity to co-develop the content and layout of the chip with a new set of algorithms tailored for diagnostic applications.”

Dr Udo Koehler, Head of Cytogenetics, MGZ Munich, confirmed, “We have investigated over 200 patients using the v1.1 CytoChip and found it a very robust platform for clinical diagnostics.

The combination of new the v2 CytoChips and BlueFuse algorithms will enable us to further enhance our service because, in contrast to conventional wisdom, we are able to increase the resolution of our investigations, while keeping interpretation simple and detection of polymorphisms to a minimum.”

Advertisement